Enhancing tumor T cell infiltration to enable cancer immunotherapy

Papers of special note have been highlighted as: • of interest

References

• 1 Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14(12), 717–734 (2017).
  Medline CASGoogle Scholar
• 2 Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S. Immunotherapy in tumors. Dtsch Arztebl. Int. 112(48), 809–815 (2015).
  MedlineGoogle Scholar
• 3 Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 359(6382), 1350–1355 (2018).
  Medline CASGoogle Scholar
• 4 Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568–571 (2014). • Shows that clinical response to PD-1 blockade depends on pre-existing intratumoral CD8+ T cells.
  Medline CASGoogle Scholar
• 5 Haanen JBAG. Converting cold into hot tumors by combining immunotherapies. Cell 170(6), 1055–1056 (2017).
  Medline CASGoogle Scholar
• 6 Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr. Opin. Immunol. 41, 23–31 (2016).
  Medline CASGoogle Scholar
• 7 Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6(5), 383–393 (2006).
  Medline CASGoogle Scholar
• 8 Cadilha B. Enabling T Cell recruitment to tumours as a strategy for improving adoptive T Cell therapy. Eur. Oncol. Haematol. 13(1), 66–73 (2017).
  Google Scholar
• 9 Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676–1680 (1988).
  Medline CASGoogle Scholar
• 10 Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233–5239 (2008).
  Medline CASGoogle Scholar
• 11 Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86(15), 1159–1166 (1994).
  Medline CASGoogle Scholar
• 12 Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 135 (2014).
  Medline CASGoogle Scholar
• 13 Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3), 535–546 (2009).
  Medline CASGoogle Scholar
• 14 Parkhurst MR, Yang JC, Langan RC et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19(3), 620–626 (2011).
  Medline CASGoogle Scholar
• 15 Rapoport AP, Stadtmauer EA, Binder-Scholl GK et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21(8), 914–921 (2015).
  Medline CASGoogle Scholar
• 16 Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917–924 (2011).
  MedlineGoogle Scholar
• 17 Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368(16), 1509–1518 (2013).
  Medline CASGoogle Scholar
• 18 Kochenderfer JN, Somerville RPT, Lu T et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol. Ther. 25(10), 2245–2253 (2017).
  Medline CASGoogle Scholar
• 19 Buechner J, Grupp SA, Maude SL et al. Global registration trial of efficacy and safety of CTL019 in Pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): update to the interim analysis. Clin. Lymphoma Myeloma Leuk. 17, S263–S264 (2017).
  MedlineGoogle Scholar
• 20 Locke FL, Neelapu SS, Bartlett NL et al. Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL). J. Clin. Oncol. 35(15_suppl), 7512–7512 (2017).
  Google Scholar
• 21 European Medicines Agency. Scientific recommendation on classification of advanced therapy medicinal products. Available at: www.ema.europa.eu/documents/report/scientific-recommendation-classification-advanced-therapy-medicinal-products-autologous-engineered_en.pdf (2016).
  Google Scholar
• 22 Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18(4), 843–851 (2010).
  Medline CASGoogle Scholar
• 23 Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra225 (2014).
  Google Scholar
• 24 Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348(6230), 62–68 (2015).
  Medline CASGoogle Scholar
• 25 Pagès F, Mlecnik B, Marliot F et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391(10135), 2128–2139 (2018). • Demonstrates that the immunoscore is a reliable parameter for cancer classification with prognostic value.
  MedlineGoogle Scholar
• 26 Galon J, Mlecnik B, Bindea G et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol. 232(2), 199–209 (2014).
  Medline CASGoogle Scholar
• 27 Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 25(2), 261–267 (2013).
  Medline CASGoogle Scholar
• 28 Galon J, Pagès F, Marincola FM et al. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 10, 1 (2012).
  MedlineGoogle Scholar
• 29 Lim WA, June CH. The Principles of engineering immune cells to treat cancer. Cell 168(4), 724–740 (2017).
  Medline CASGoogle Scholar
• 30 Mrass P, Takano H, Ng LG et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J. Exp. Med. 203(12), 2749–2761 (2006).
  Medline CASGoogle Scholar
• 31 Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17(9), 559–572 (2017). • Summarizes the functions of chemokines in the tumor microenvironment and chemokine-related therapies.
  Medline CASGoogle Scholar
• 32 Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat. Rev. Cancer 18(9), 533–549 (2018).
  Medline CASGoogle Scholar
• 33 Motz GT, Santoro SP, Wang LP et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20(6), 607–615 (2014).
  Medline CASGoogle Scholar
• 34 Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12(4), 298–306 (2012).
  Medline CASGoogle Scholar
• 35 Peske JD, Woods AB, Engelhard VH. Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment. Adv. Cancer Res. 128, 263–307 (2015).
  Medline CASGoogle Scholar
• 36 Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7(9), 678–689 (2007).
  Medline CASGoogle Scholar
• 37 Constantin G, Majeed M, Giagulli C et al. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity 13(6), 759–769 (2000).
  Medline CASGoogle Scholar
• 38 Shamri R, Grabovsky V, Gauguet JM et al. Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines. Nat. Immunol. 6(5), 497–506 (2005).
  Medline CASGoogle Scholar
• 39 Kinashi T. Intracellular signalling controlling integrin activation in lymphocytes. Nat. Rev. Immunol. 5(7), 546–559 (2005).
  Medline CASGoogle Scholar
• 40 Girard JP, Moussion C, Förster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat. Rev. Immunol. 12(11), 762–773 (2012).
  Medline CASGoogle Scholar
• 41 Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat. Rev. Immunol. 13(5), 309–320 (2013).
  Medline CASGoogle Scholar
• 42 Orimo A, Weinberg RA. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol. Ther. 6(4), 618–619 (2007).
  Medline CASGoogle Scholar
• 43 Liao Z, Tan ZW, Zhu P, Tan NS. Cancer-associated fibroblasts in tumor microenvironment – accomplices in tumor malignancy. Cell Immunol. pii: S0008-8749(17)30222-8 (2018).
  MedlineGoogle Scholar
• 44 Salmon H, Franciszkiewicz K, Damotte D et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122(3), 899–910 (2012). • Shows that more T cells accumulate in stromal than in tumor islets in human lung tumors. Matrix reduction with collagenase increased T cells entering into the tumor.
  Medline CASGoogle Scholar
• 45 Kraman M, Bambrough PJ, Arnold JN et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330(6005), 827–830 (2010).
  Medline CASGoogle Scholar
• 46 Feig C, Jones JO, Kraman M et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110(50), 20212–20217 (2013).
  Medline CASGoogle Scholar
• 47 Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in Cancer. Vasc. Health Risk Manag. 2(3), 213–219 (2006).
  Medline CASGoogle Scholar
• 48 Hamzah J, Jugold M, Kiessling F et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453(7193), 410–414 (2008). • Demonstrates that genetic ablation of a vascular gene can reduce tumor angiogenesis and improve the effect of immune therapy.
  Medline CASGoogle Scholar
• 49 Forster JC, Harriss-Phillips WM, Douglass MJ, Bezak E. A review of the development of tumor vasculature and its effects on the tumor microenvironment. Hypoxia (Auckl.) 5, 21–32 (2017).
  MedlineGoogle Scholar
• 50 Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 181(2), 811–816 (1995).
  Medline CASGoogle Scholar
• 51 Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 56(5), 1111–1117 (1996).
  Medline CASGoogle Scholar
• 52 Hellwig SM, Damen CA, van Adrichem NP, Blijham GH, Groenewegen G, Griffioen AW. Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors. Cancer Lett. 120(2), 203–211 (1997).
  Medline CASGoogle Scholar
• 53 Johansson A, Hamzah J, Payne CJ, Ganss R. Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc. Natl Acad. Sci. USA 109(20), 7841–7846 (2012).
  Medline CASGoogle Scholar
• 54 Calcinotto A, Grioni M, Jachetti E et al. Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J. Immunol. 188(6), 2687–2694 (2012).
  Medline CASGoogle Scholar
• 55 Borsi L, Balza E, Carnemolla B et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102(13), 4384–4392 (2003).
  Medline CASGoogle Scholar
• 56 Elia AR, Grioni M, Basso V et al. Targeting tumor vasculature with TNF leads effector T cells to the tumor and enhances therapeutic efficacy of immune checkpoint blockers in combination with adoptive cell therapy. Clin. Cancer Res. 24(9), 2171–2181 (2018).
  Medline CASGoogle Scholar
• 57 Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271(1), 260–275 (2016).
  Medline CASGoogle Scholar
• 58 Johansson-Percival A, He B, Li ZJ et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat. Immunol. 18(11), 1207–1217 (2017). • Shows that the induction of intratumoral lymphoid structures improves the efficacy of immunotherapies.
  Medline CASGoogle Scholar
• 59 Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6, 7114 (2015).
  Medline CASGoogle Scholar
• 60 Joshi NS, Akama-Garren EH, Lu Y et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43(3), 579–590 (2015).
  Medline CASGoogle Scholar
• 61 Kasic T, Colombo P, Soldani C et al. Modulation of human T-cell functions by reactive nitrogen species. Eur. J. Immunol. 41(7), 1843–1849 (2011).
  Medline CASGoogle Scholar
• 62 Bronte V, Kasic T, Gri G et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201(8), 1257–1268 (2005).
  Medline CASGoogle Scholar
• 63 Nagaraj S, Gupta K, Pisarev V et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13(7), 828–835 (2007).
  Medline CASGoogle Scholar
• 64 Molon B, Ugel S, Del Pozzo F et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208(10), 1949–1962 (2011).
  Medline CASGoogle Scholar
• 65 Janssens R, Mortier A, Boff D et al. Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity in vitro and abrogates intra-articular lymphocyte recruitment in vivo. Oncotarget 7(38), 62439–62459 (2016).
  MedlineGoogle Scholar
• 66 Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32, 659–702 (2014).
  Medline CASGoogle Scholar
• 67 Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203–213 (2003).
  Medline CASGoogle Scholar
• 68 Pagès F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353(25), 2654–2666 (2005).
  Medline CASGoogle Scholar
• 69 Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960–1964 (2006).
  Medline CASGoogle Scholar
• 70 Walch-Rückheim B, Mavrova R, Henning M et al. Stromal fibroblasts induce CCL20 through IL6/C/EBPβ to support the recruitment of Th17 cells during cervical cancer progression. Cancer Res. 75(24), 5248–5259 (2015).
  Medline CASGoogle Scholar
• 71 Bell D, Chomarat P, Broyles D et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190(10), 1417–1426 (1999).
  Medline CASGoogle Scholar
• 72 Scotton CJ, Wilson JL, Scott K et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62(20), 5930–5938 (2002).
  Medline CASGoogle Scholar
• 73 Kryczek I, Lange A, Mottram P et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65(2), 465–472 (2005).
  Medline CASGoogle Scholar
• 74 Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942–949 (2004).
  Medline CASGoogle Scholar
• 75 Qian BZ, Li J, Zhang H et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475(7355), 222–225 (2011).
  Medline CASGoogle Scholar
• 76 Kitamura T, Qian BZ, Soong D et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J. Exp. Med. 212(7), 1043–1059 (2015).
  Medline CASGoogle Scholar
• 77 Yang L, Huang J, Ren X et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13(1), 23–35 (2008).
  Medline CASGoogle Scholar
• 78 Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014 292376 (2014).
  MedlineGoogle Scholar
• 79 Halama N, Zoernig I, Berthel A et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell 29(4), 587–601 (2016).
  Medline CASGoogle Scholar
• 80 Zumwalt TJ, Arnold M, Goel A, Boland CR. Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. Oncotarget 6(5), 2981–2991 (2015).
  MedlineGoogle Scholar
• 81 Zimmermann T, Moehler M, Gockel I et al. Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. Int. J. Colorectal Dis. 25(4), 417–424 (2010).
  MedlineGoogle Scholar
• 82 Peng D, Kryczek I, Nagarsheth N et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527(7577), 249–253 (2015).
  Medline CASGoogle Scholar
• 83 Nagarsheth N, Peng D, Kryczek I et al. PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer. Cancer Res. 76(2), 275–282 (2016).
  Medline CASGoogle Scholar
• 84 Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523(7559), 231–235 (2015).
  Medline CASGoogle Scholar
• 85 Mojsilovic-Petrovic J, Callaghan D, Cui H, Dean C, Stanimirovic DB, Zhang W. Hypoxia-inducible factor-1 (HIF-1) is involved in the regulation of hypoxia-stimulated expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) and MCP-5 (Ccl12) in astrocytes. J. Neuroinflamm. 4, 12 (2007).
  MedlineGoogle Scholar
• 86 Végran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 71(7), 2550–2560 (2011).
  Medline CASGoogle Scholar
• 87 Idorn M, Thor Straten P. Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site. Cells 7(8) (2018).
  MedlineGoogle Scholar
• 88 Koga M, Kai H, Egami K et al. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem. Biophys. Res. Commun. 365(2), 279–284 (2008).
  Medline CASGoogle Scholar
• 89 Hong M, Puaux AL, Huang C et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 71(22), 6997–7009 (2011).
  Medline CASGoogle Scholar
• 90 Dieci MV, Criscitiello C, Goubar A et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann. Oncol. 25(3), 611–618 (2014).
  Medline CASGoogle Scholar
• 91 Brambilla E, Le Teuff G, Marguet S et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J. Clin. Oncol. 34(11), 1223–1230 (2016).
  Medline CASGoogle Scholar
• 92 Peng W, Liu C, Xu C et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. 72(20), 5209–5218 (2012).
  Medline CASGoogle Scholar
• 93 Spear P, Barber A, Sentman CL. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology 2(4), e23564 (2013).
  MedlineGoogle Scholar
• 94 Sugiyama D, Nishikawa H, Maeda Y et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl Acad. Sci. USA 110(44), 17945–17950 (2013).
  Medline CASGoogle Scholar
• 95 Nakagawa M, Schmitz R, Xiao W et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J. Exp. Med. 211(13), 2497–2505 (2014).
  Medline CASGoogle Scholar
• 96 Hoelzinger DB, Smith SE, Mirza N, Dominguez AL, Manrique SZ, Lustgarten J. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J. Immunol. 184(12), 6833–6842 (2010).
  Medline CASGoogle Scholar
• 97 Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161(2), 927–932 (1998).
  Medline CASGoogle Scholar
• 98 Wagers AJ, Waters CM, Stoolman LM, Kansas GS. Interleukin 12 and interleukin 4 control T cell adhesion to endothelial selectins through opposite effects on alpha1, 3-fucosyltransferase VII gene expression. J. Exp. Med. 188(12), 2225–2231 (1998).
  Medline CASGoogle Scholar
• 99 Tsai AK, Davila E. Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors. Oncoimmunology 5(5), e1122158 (2016).
  MedlineGoogle Scholar
• 100 Zhang L, Morgan RA, Beane JD et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 21(10), 2278–2288 (2015).
  Medline CASGoogle Scholar
• 101 Hu B, Ren J, Luo Y et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20(13), 3025–3033 (2017).
  Medline CASGoogle Scholar
• 102 Hoyos V, Savoldo B, Quintarelli C et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24(6), 1160–1170 (2010).
  Medline CASGoogle Scholar
• 103 Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050–1063 (2007).
  Medline CASGoogle Scholar
• 104 McCabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427), 108–112 (2012).
  Medline CASGoogle Scholar
• 105 Sapoznik S, Ortenberg R, Galore-Haskel G et al. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol. Immunother. 61(10), 1833–1847 (2012).
  Medline CASGoogle Scholar
• 106 Kershaw MH, Wang G, Westwood JA et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13(16), 1971–1980 (2002).
  Medline CASGoogle Scholar
• 107 Idorn M, Thor Straten P, Svane IM, Met Ö. Transfection of tumor-infiltrating T cells with mRNA encoding CXCR2. Methods Mol. Biol. 1428, 261–276 (2016).
  Medline CASGoogle Scholar
• 108 Peng W, Ye Y, Rabinovich BA et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 16(22), 5458–5468 (2010).
  Medline CASGoogle Scholar
• 109 Rapp M, Grassmann S, Chaloupka M et al. C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. Oncoimmunology 5(3), e1105428 (2016).
  MedlineGoogle Scholar
• 110 Di Stasi A, De Angelis B, Rooney CM et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113(25), 6392–6402 (2009).
  Medline CASGoogle Scholar
• 111 Craddock JA, Lu A, Bear A et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33(8), 780–788 (2010).
  Medline CASGoogle Scholar
• 112 Moon EK, Carpenito C, Sun J et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17(14), 4719–4730 (2011).
  Medline CASGoogle Scholar
• 113 Siddiqui I, Erreni M, van Brakel M, Debets R, Allavena P. Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J. Immunother. Cancer 4, 21 (2016).
  MedlineGoogle Scholar
• 114 Dirkx AE, Oude Egbrink MG, Kuijpers MJ et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 63(9), 2322–2329 (2003).
  Medline CASGoogle Scholar
• 115 Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70(15), 6171–6180 (2010).
  Medline CASGoogle Scholar
• 116 Dirkx AE, oude Egbrink MG, Castermans K et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20(6), 621–630 (2006).
  Medline CASGoogle Scholar
• 117 Griffioen AW. Anti-angiogenesis: making the tumor vulnerable to the immune system. Cancer Immunol. Immunother. 57(10), 1553–1558 (2008).
  Medline CASGoogle Scholar
• 118 Wong NS, Buckman RA, Clemons M et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J. Clin. Oncol. 28(5), 723–730 (2010).
  Medline CASGoogle Scholar
• 119 Legler DF, Johnson-Léger C, Wiedle G, Bron C, Imhof BA. The alpha v beta 3 integrin as a tumor homing ligand for lymphocytes. Eur. J. Immunol. 34(6), 1608–1616 (2004).
  Medline CASGoogle Scholar
• 120 Cantor JM, Rose DM, Slepak M, Ginsberg MH. Fine-tuning tumor immunity with integrin trans-regulation. Cancer Immunol. Res. 3(6), 661–667 (2015).
  Medline CASGoogle Scholar
• 121 Samaha H, Pignata A, Fousek K et al. A homing system targets therapeutic T cells to brain cancer. Nature 561(7723), 331–337 (2018).
  Medline CASGoogle Scholar
• 122 Klinger M, Benjamin J, Kischel R, Stienen S, Zugmaier G. Harnessing T cells to fight cancer with BiTE^® antibody constructs – past developments and future directions. Immunol Rev. 270(1), 193–208 (2016). • Summarizes the usage of bispecific antibodies to treat cancer.
  Medline CASGoogle Scholar
• 123 Kobold S, Steffen J, Chaloupka M et al. Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. J. Natl. Cancer Inst. 107(1), 364 (2015).
  MedlineGoogle Scholar